NAME :- BRINZOLAMIDE
IUPAC NAME :- (5R)-5-ethylamino-3-(3-methoxypropyl)-2,2-dioxo-2λ6,9-dithia-3-azabicyclo[4.3.0]nona-7,10-diene-8-sulfonamide
CAS NO. :- 138890-62-7
FORMULA :- C12H21N3O5S3
SYNONYMS :- AL 4;Azopt;AL-4682;AL 4862;BRINZOLAMIDE;BIRNZOLAMIDE;Brinlolamide;Brinzolamide (200 mg);(4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide;(4R)-4-(ethylamino)-1,1-diketo-2-(3-methoxypropyl)-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide
APPLICATION :- For the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
DESCRIPTION :- Brinzolamide is a highly specific, non-competitive, reversible carbonic anhydrase inhibitor. Carbonic anhydrase (CA) is an enzyme found in many tissues of the body including the eye. It catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II (CA-II). Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. The result is a reduction in intraocular pressure. Brinzolamide is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.